Tamoxifen (Record no. 45252)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 03559nam a22005417a 4500 |
001 - CONTROL NUMBER | |
control field | sulb-eb0023160 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | BD-SySUS |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20160413122337.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 130723s2013 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9783034806640 |
-- | 978-3-0348-0664-0 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1007/978-3-0348-0664-0 |
Source of number or code | doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RC261-271 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MJCL |
Source | bicssc |
Subject category code | MED062000 |
Source | bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 614.5999 |
Edition number | 23 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Maximov, Philipp Y. |
Relator term | author. |
245 10 - TITLE STATEMENT | |
Title | Tamoxifen |
Medium | [electronic resource] : |
Remainder of title | Pioneering Medicine in Breast Cancer / |
Statement of responsibility, etc. | by Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | Basel : |
Name of producer, publisher, distributor, manufacturer | Springer Basel : |
-- | Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice | 2013. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | XXII, 202 p. |
Other physical details | online resource. |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS | |
File type | text file |
Encoding format | |
Source | rda |
490 1# - SERIES STATEMENT | |
Series statement | Milestones in Drug Therapy |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens -- Tamoxifen Goes Forward Alone -- Metabolites of Tamoxifen as the Basis of Drug Development -- Adjuvant Therapy – The Breakthrough -- The Wisconsin Story in the 1980’s: Discovery of Target Site Specific Estrogen Action -- Carcinogenesis and Tamoxifen -- Chemoprevention: Cinderella waiting for the ball -- Tamoxifen and Raloxifene head to head: The STAR TRIAL -- Acquired resistance to Tamoxifen: back to the beginning -- The legacy of Tamoxifen -- Appendix: Four decades of discovery in breast cancer research and treatment – an interview with V. Craig Jordan by Marc Poirot -- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine. |
520 ## - SUMMARY, ETC. | |
Summary, etc. | Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Medicine. |
Topical term or geographic name as entry element | Cancer research. |
Topical term or geographic name as entry element | Pharmacology. |
Topical term or geographic name as entry element | Endocrinology. |
Topical term or geographic name as entry element | Oncology. |
Topical term or geographic name as entry element | Biomedicine. |
Topical term or geographic name as entry element | Cancer Research. |
Topical term or geographic name as entry element | Pharmacology/Toxicology. |
Topical term or geographic name as entry element | Oncology. |
Topical term or geographic name as entry element | Endocrinology. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | McDaniel, Russell E. |
Relator term | author. |
Personal name | Jordan, V. Craig. |
Relator term | author. |
710 2# - ADDED ENTRY--CORPORATE NAME | |
Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY | |
Title | Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Printed edition: |
International Standard Book Number | 9783034806633 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Milestones in Drug Therapy |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://dx.doi.org/10.1007/978-3-0348-0664-0">http://dx.doi.org/10.1007/978-3-0348-0664-0</a> |
912 ## - | |
-- | ZDB-2-SBL |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Source of classification or shelving scheme | |
Koha item type |
No items available.